Zentalis Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $198.5M
- as of Sep 30, 2026
- Shares Outstanding
- 71.7M
- Free Float
- 56.8%
Income Statement
- Revenue
- $0
- Operating Income
- -$152.8M
- Net Income
- -$137.1M
- EBITDA
- -$152.1M
Cash Flow
- Free Cash Flow
- -$125.2M
- FCF Yield
- -63.1%
- Owner FCF Yield
- -73.5%
Balance Sheet
- Cash & Equivalents
- $36.0M
Returns & Capital
- Share Repurchases
- $10.0M
- Buyback Yield, 3Y Avg
- 1.7%
- SBC, 3Y Avg
- $47.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | -$125.2M | — |
| FY2024 | $67.4M | -$171.1M | -253.7% |
| FY2023 | $0 | -$208.4M | — |
| FY2022 | $0 | -$166.3M | — |
| FY2021 | — | -$160.2M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back